Replies to post #139207 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Yes, I think Celldex needs to cough up more on psPD inclusion protocol. Dr. Stupp was involved in this trial as well, and he, and many others (for good reason I might add) do not want to exclude early psPD from these trials, because they can potentially benefit from therapy. DCVax-L, who excluded psPD, is the exception, but it too had/has good reason, and personally I think that was to avoid tacking on another year or two to this incredibly long trial. Their protocol was to separately analyze early psPD, and I think they completed enrollment for that group sometime about four or more years ago for that blinded 2:1 randomized psPD group.


Here is the Dr. Liau quote you asked about as dictated by Senti:

And at minute 36.50 of the youtube video from yesterday, Linda Liau states this...


But we all do believe that there is efficacy in this and it really comes down to what potentially happened with the EGFR vaccine trial [Rindo] in terms of the endpoints and the trial design and how to best elucidate the differences here.